Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAHR-102 in Recurrent Malignant Lymphoma
NCT02545361Phase 2Withdrawn
- Sponsor
- KAHR Medical
- Start
- Apr 2018
- Primary completion
- Apr 2020
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 2, open-label, single-arm trial of KAHR-102 in lymphoma, sponsored by KAHR Medical. Primary endpoint: Incidence of Adverse Events up to 9 months. Planned start Apr 2018; status: withdrawn.
02
Drugs
KAHR-102
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT02545361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02545361.